MNPR (Monopar Therapeutics) Stock Based Compensation: $5.18 Mil (TTM As of Mar. 2026)


MNPR Monopar Therapeutics Inc MNPR
35 GF Score
Price $97.50
! 3 Warning Signs
View Full Analysis

What is Monopar Therapeutics Stock Based Compensation?

Monopar Therapeutics MNPR +2.98% 35 Stock Based Compensation is $5.18 Mil as of Mar. 2026. GuruFocus rates MNPR with a GF Score™ of 35/100. The stock has 3 warning signs investors should review.

Monopar Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was $1.69 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $5.18 Mil.

Monopar Therapeutics Stock Based Compensation Related Terms

Monopar Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Monopar Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monopar Therapeutics Stock Based Compensation Chart

Monopar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.47 1.64 1.90 1.14 4.84

Monopar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 1.28 1.10 1.10 1.69
MNPR
35GF Score
Monopar Therapeutics Inc MNPR
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monopar Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.18 Mil.

What does a Stock Based Compensation of $5.18 Mil mean?
Monopar Therapeutics (MNPR) has a Stock Based Compensation of $5.18 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Monopar Therapeutics and its competitors.
Is Monopar Therapeutics' Stock Based Compensation too high?
Monopar Therapeutics' current Stock Based Compensation is $5.18 Mil. Overall, Monopar Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' Stock Based Compensation compare to MDXG and FTH?
Monopar Therapeutics' Stock Based Compensation of $5.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Monopar Therapeutics and its competitors. Monopar Therapeutics's current Stock Based Compensation is $5.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current Stock Based Compensation of $5.18 Mil. The current Stock Based Compensation is $5.18 Mil. Monopar Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current Stock Based Compensation is $5.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monopar Therapeutics Business Description

Other Exchanges 1IY0:Germany
Address 1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
35GF Score

Get the complete analysis for MNPR

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$97.50
Price